CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life...
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall careSALT LAKE CITY,...
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and...
Guideline adoption can help end the diagnostic odyssey experienced by many families STAMFORD, Conn., Oct. 31, 2022 (GLOBE NEWSWIRE) --...
-- Rhythm to review data on webcast conference call on November 2, 2022 at 8:30 a.m. ET – -- Rhythm...
Research from 19,000 patients with Autism Spectrum Disorders found approximately 90% had prior negative tests, likely contributing to a longer...
-- Approximately 100 European health care professionals invited to discuss recent scientific developments in rare pathway-related obesities -- -- Rhythm...
SALT LAKE CITY, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine,...
Understanding Hunger & Bardet-Biedl Syndrome (BBS): Gabe’s Story Developed in collaboration with the Bardet-Biedl Syndrome (BBS) Foundation-- Book developed in...
LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Revenue of US$51.7 million in the second quarter of 2022Loss from operations of US$(17.9) million and adjusted EBITDA1 of US$6.5...
Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapySALT LAKE...
Preparations for Tollovir™ Phase 2 Trial Extension to Support EUA Filing Now Complete Preparations for Tollovid™ Phase 2 Trial in...
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
MELBOURNE, Australia, July 28, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader...
BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads...
-- European Commission decision anticipated in fourth quarter of 2022 -- BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals,...
Renowned Experts to Support ColoAlert’s U.S. Pivotal Clinical Trial and Development of Additional Cancer DiagnosticsDr. Wang is the GI (Gastrointestinal)...